Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review

Junqiang Yan; Anran Liu; Jiarui Huang; Jiannan Wu; Ruile Shen; Hongxia Ma; Jianxue Yang

doi:10.3389/fnagi.2021.709878

Pharmacological Interventions for REM Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review

Front Aging Neurosci. 2021 Aug 13:13:709878. doi: 10.3389/fnagi.2021.709878. eCollection 2021.

Authors

Junqiang Yan^{1

2}, Anran Liu², Jiarui Huang², Jiannan Wu¹, Ruile Shen², Hongxia Ma², Jianxue Yang^{1

3}

Affiliations

¹ Key Laboratory of Neuromolecular Biology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
² Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
³ School of Nursing, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.

Abstract

To review the therapeutic effects of drugs on REM sleep behavior disorder (RBD) in Parkinson's disease (PD) by searching the MEDLINE/PubMed, Embase, Cochrane, and CBM databases. According to the inclusion and exclusion criteria, studies were included after excluding duplicate data. We evaluated the safety and efficacy of pharmacological intervention to improve RBD in patients with Parkinson's disease (PD-RBD). This systematic review mainly describes the drugs that can be used to treat PD-RBD patients. The results have shown that melatonin can be used as the first-line drug for PD-RBD, and clonazepam provides significant improvement on PD-RBD, androtigotine can be used as an alternative drug. However, further large-scale clinical trial studies are still needed to provide the best guidelines for the pharmacological treatment of PD-RBD.

Keywords: Parkinson's disease; drugs; rapid eye movement; sleep; systematic review.

Publication types

Systematic Review